Overview

A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden

Status:
RECRUITING

Trial end date:
2026-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema (atopic dermatitis), but these places may be very itchy. Participation in this study will last up to approximately 38 weeks (9 and a half months) including 24 weeks (6 months) of treatment.

Phase:

PHASE4

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

lebrikizumab